tiprankstipranks
Advertisement
Advertisement
Toast downgraded, Lowe’s upgraded: Wall Street’s top analyst calls
PremiumThe FlyToast downgraded, Lowe’s upgraded: Wall Street’s top analyst calls
1M ago
Lenz Therapeutics price target raised to $31 from $29 at BofA
Premium
The Fly
Lenz Therapeutics price target raised to $31 from $29 at BofA
1M ago
Analyst Reiterates Buy on LENZ Amid Strong Early Commercial Execution and Durable Demand Signals
Premium
Ratings
Analyst Reiterates Buy on LENZ Amid Strong Early Commercial Execution and Durable Demand Signals
1M ago
Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)
PremiumThe FlyLenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)
1M ago
Lenz Therapeutics, Inc. (LENZ) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Lenz Therapeutics, Inc. (LENZ) Q1 Earnings Cheat Sheet
2M ago
LENZ Therapeutics: Early VIZZ Launch Traction Supports Buy Rating Despite Trimmed Near‑Term Outlook
Premium
Ratings
LENZ Therapeutics: Early VIZZ Launch Traction Supports Buy Rating Despite Trimmed Near‑Term Outlook
2M ago
Buy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
PremiumRatingsBuy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
3M ago
Lenz Therapeutics price target lowered to $29 from $35 at BofA
Premium
The Fly
Lenz Therapeutics price target lowered to $29 from $35 at BofA
3M ago
Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
Premium
The Fly
Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100